We are live on !
Find out more
Daniel Devine & Co Portfolio holdings
AUM
$125M
Turnover
9.62%
1-Year Est. Return
14.12%
This Fund
S&P 500
This Quarter Est. Return
+3.43%
1 Year Est. Return
+14.12%
3 Year Est. Return
+34.19%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$125M
AUM Growth
+$1.99M
(+1.6%)
Cap. Flow
-$1.63M
Cap. Flow % of AUM
Cap. Flow %
-1.31%
Top 10 Holdings %
Top 10 Hldgs %
65.84%
Holding
52
New
1
Increased
13
Reduced
13
Closed
4
Avg Time Held
2.7
years
Top 10 Avg Time Held
2.5
years
Top 20 Avg Time Held
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walmart Inc
WMT
|
+$1.71M |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$887K |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$402K |
| 4 |
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
|
+$352K |
| 5 |
SAP
SAP
|
+$113K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Target
TGT
|
+$1.33M |
| 2 |
AstraZeneca
AZN
|
+$827K |
| 3 |
Hanesbrands
HBI
|
+$821K |
| 4 |
RDS.B
Royal Dutch Shell PLC ADS Class B
RDS.B
|
+$353K |
| 5 |
AbbVie
ABBV
|
+$342K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 56.55% |
| 2 | Healthcare | 11.52% |
| 3 | Financials | 7.87% |
| 4 | Technology | 7.08% |
| 5 | Industrials | 4.16% |
No holdings matched the selected filter criteria.
Similar funds
KFA
MGA
MAI
ACM
Daniel Devine & Co's Q2 2018 Portfolio in Review
As of Q2 2018, Daniel Devine & Co held 52 positions worth $125M, up 1.6% from $123M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Daniel Devine & Co's Q2 2018 filing shows 1 new, 13 increased, 13 reduced and 4 closed positions. Its largest new stake was Walmart Inc: 60,075 shares worth $1.72M. The largest sale was Target, an estimated $1.33M.
By sector, the portfolio is most concentrated in Miscellaneous at 57% of assets, up from 54% a quarter earlier, followed by Healthcare and Financials.
- Daniel Devine & Co's largest Q2 2018 buy was Walmart Inc: 60,075 shares worth $1.72M.
- Daniel Devine & Co added most to Vanguard S&P 500 ETF in Q2 2018, an estimated $887K increase.
- Daniel Devine & Co's biggest Q2 2018 reduction was AstraZeneca, cutting an estimated $827K.
- Daniel Devine & Co fully exited Target in Q2 2018, selling an estimated $1.33M.
- Daniel Devine & Co's ten largest holdings make up 66% of its $125M portfolio in Q2 2018.
- Daniel Devine & Co opened 1 new position and closed 4 in Q2 2018.
- Daniel Devine & Co's portfolio value rose 1.6% quarter-over-quarter to $125M.
Based on Daniel Devine & Co's 13F filing for Q2 2018, filed 18 Jul 2018.